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1Aortic stenosis is the most common form of valve disease in the Western world and a major healthcare burden that 
is set to treble by 2050. However, we currently lack any dis-
ease-modifying therapies. Calcification seems to be the pre-
dominant pathological process driving disease progression, 
leading to major interest in novel treatment strategies aimed at 
reducing calcification activity in the valve.1 However, assess-
ing the efficacy of new therapies requires large trials with 
prolonged follow-up to demonstrate an impact on disease 
progression and clinical end points.2 A noninvasive imaging 
technique capable of measuring calcification activity in the 
valve would be highly desirable to assess treatment efficacy 
in phase 2 clinical trials.
See Editorial by Chang and Chareonthaitawee
See Clinical Perspective
18F-Fluoride is a positron-emitting radiotracer that binds 
to regions of newly developing microcalcification beyond the 
Background—18F-Fluoride positron emission tomography (PET) and computed tomography (CT) can measure disease 
activity and progression in aortic stenosis. Our objectives were to optimize the methodology, analysis, and scan–rescan 
reproducibility of aortic valve 18F-fluoride PET-CT imaging.
Methods and Results—Fifteen patients with aortic stenosis underwent repeated 18F-fluoride PET-CT. We compared 
nongated PET and noncontrast CT, with a modified approach that incorporated contrast CT and ECG-gated PET. We 
explored a range of image analysis techniques, including estimation of blood-pool activity at differing vascular sites and 
a most diseased segment approach. Contrast-enhanced ECG-gated PET-CT permitted localization of 18F-fluoride uptake 
to individual valve leaflets. Uptake was most commonly observed at sites of maximal mechanical stress: the leaflet tips 
and the commissures. Scan–rescan reproducibility was markedly improved using enhanced analysis techniques leading 
to a reduction in percentage error from ±63% to ±10% (tissue to background ratio MDS mean of 1.55, bias −0.05, limits 
of agreement −0·20 to +0·11).
Conclusions—Optimized 18F-fluoride PET-CT allows reproducible localization of calcification activity to different regions 
of the aortic valve leaflet and commonly to areas of increased mechanical stress. This technique holds major promise in 
improving our understanding of the pathophysiology of aortic stenosis and as a biomarker end point in clinical trials of 
novel therapies.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02132026.   
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resolution of computed tomography.3 It is readily taken up by 
the valves of patients with aortic stenosis, and, on histology, 
correlates with markers of calcification activity.4 Importantly, 
this technique predicts disease progression both with respect 
to echocardiography and computed tomography (CT) calcium 
scoring and with respect to adverse cardiovascular events.5–7 
18F-Fluoride positron emission tomography (PET) imaging 
therefore holds major promise as a marker of calcification 
activity in aortic stenosis and is an exploratory secondary end 
point in the ongoing SALTIRE2 clinical trial (NCT02132026). 
Briefly, this is a randomized controlled trial investigating the 
ability of therapies targeting calcium metabolism (denosumab 
and alendronic acid) to modify disease progression in aortic 
stenosis.
Here, we sought to optimize 18F-fluoride PET scanning 
of the aortic valve, reduce the effects of cardiac motion, and 
assess the scan–rescan reproducibility of this technique to 
inform its future application as a novel biomarker of calcifica-
tion activity in clinical trials.
Methods
Study Population
Patients aged >50 years with mild, moderate, and severe calcific 
aortic stenosis were recruited prospectively from outpatient clinics 
at the Edinburgh Heart Center. Aortic stenosis severity was deter-
mined by clinical echocardiograms and graded according to accord-
ing to American Heart Association/American College of Cardiology 
guidelines. This is a substudy of the ongoing SALTIRE2 clinical trial 
(NCT02132026), and consequently patients had to meet the same 
exclusion criteria as those entering the main trial. These included re-
nal failure and women of childbearing potential (full list in Table I 
in the Data Supplement). The study was approved by the Scottish 
Research Ethics Committee and has a Clinical Trial Authorization 
from the Medicines and Healthcare products Regulatory Authority 
of the United Kingdom. It was performed in accordance with the 
Declaration of Helsinki. All patients gave written informed consent.
Initial Image Acquisition and Analysis
Each patient underwent 18F-fluoride PET and CT scanning on 2 oc-
casions. Patients were given 25 mg of oral metoprolol if their resting 
heart rate was >65 beats/min before being administered 125 MBq 
of 18F-fluoride IV. After 60 minutes, patients were imaged with a 
hybrid PET and CT scanner (Biograph mCT; Siemens). Attenuation-
correction CT scans were performed before acquisition of PET data 
in list mode using a single 30-minute bed position centered on the 
valve in 3-dimensional mode. Finally, ECG-gated aortic valve CT 
calcium scoring and contrast-enhanced CT angiography were per-
formed in diastole and in held expiration.
CT calcium scoring was performed by an experienced operator 
using dedicated software (Vitrea Advanced; Toshiba Systems) on 
axial views, with care taken to exclude calcium originating from the 
ascending aorta, left ventricular outflow tract, and coronary arteries. 
The calcium score was recorded in Agatston units.
Analysis was performed using an OsiriX workstation (OsiriX ver-
sion 3.5.1 64-bit; OsiriX Imaging Software, Geneva, Switzerland). 
As previously reported, regions of interest were drawn around the 
perimeter of the valve on the fused nongated PET and noncontrast 
CT images.6 These generated mean and maximum standard uptake 
values (SUV) for each slice. Averaging these values across the entire 
valve produced whole valve SUV
mean
 and SUV
max
 values, respective-
ly. These SUV values were then corrected for blood-pool activity to 
generate tissue to background ratio (TBR): whole valve TBR
mean
 and 
TBR
max
. The blood-pool uptake was determined using SUV
mean
 val-
ues averaged from across regions of interest drawn on 5 contiguous 
slices in the brachiocephalic vein. For consistency, the most caudal 
region of interest was positioned at the point where the innominate 
vein joined the brachiocephalic vein.6
To optimize the spatial localization and scan–rescan reproduc-
ibility of 18F-fluoride PET-CT imaging, we assessed different ap-
proaches to both image acquisition and image analysis.
Optimization of PET Image Acquisition
Contrast CT of Aortic Valve
Our original technique required the reorientation and coregistration 
of noncontrast CT images of the aortic valve. This technique posed 
several challenges, particularly with respect to aligning with the true 
plane of the valve and accurately defining its perimeter. Moreover, 
the structure of individual leaflets was not visible on these scans pre-
cluding more detailed localization of 18F-fluoride uptake. Contrast 
CT offered potential solutions to these challenges given its superior 
anatomic detail and the well-established methodology for finding the 
true plane of the valve8 (Figure 1).
ECG-Gated PET Data
PET is susceptible to motion, limiting accurate coregistration and the 
spatial assessment of PET activity within the valve. As a solution, we 
used ECG gating of list-mode PET data. These data were reconstructed 
into 4 gates at 25% intervals of the cardiac cycle. Only data acquired 
between 50% and 75% of the RR interval were assessed because this 
period corresponds with diastole when cardiac motion is at a minimum. 
Given that 3 quarters of the PET data are therefore discarded, the bed-
time was increased to 30 minutes to preserve signal to noise ratio.
Optimization of PET Image Analysis
Measurement of Blood-Pool Activity
The stability of blood-pool measurements in the SVC for 18F-fluoride–
based tracers has recently been questioned,9 and we were concerned 
about variation in the measured blood-pool activity at different levels 
of the brachiocephalic vein. We reasoned that this may be explained 
by the relatively small diameter of this vein rendering it susceptible to 
partial volume effects, amplified by the low PET signal in surround-
ing lung tissue (especially in the cranial aspects of the brachocephalic 
vein). We hypothesized that sampling blood-pool activity from the 
center of the right atrium (a much larger structure) may improve the 
ease and accuracy with which these measurements could be made and 
the consequent scan–rescan reproducibility. Using the same coregis-
tered PET and CT images of the heart, reorientated to the plane of the 
valve, a 2-cm2 region of interest was drawn in the center of the right 
atrium at the level of the right coronary ostium and again in the same 
position one slice superiorly. Averaging the mean SUV for these 2 slic-
es gave an alternative measure of blood-pool activity, which was used 
to correct valvular uptake measurements using 2 different approaches. 
First, we used the conventional method of dividing aortic valve SUV 
measurements by the blood pool to generate TBR values. Second, we 
subtracted the blood-pool value from the valvular uptake, to generate 
the corrected aortic valve SUV as described recently.9
Most Diseased Segment and Whole Valve Approach
One of the biggest difficulties in quantifying uptake in the valve is 
defining its limits in the z-plane. To overcome this challenge, our 
original whole valve technique was compared with a most diseased 
segment (MDS) approach where the 2 contiguous slices with the 
highest SUV values (frequently in the center of the valve) were av-
eraged to generate SUVMDSmean, SUVMDSmax, and corresponding TBR 
values. This is similar to the approach previously used for quantify-
ing 18F-fluorodeoxyglucose uptake in carotid and aortic atheroma.10
Scan–Rescan Reproducibility
Scan–rescan repeatability and intra- and interobserver reproducibil-
ity of valvular 18F-fluoride PET quantification was assessed for each 
of the established and novel image analysis approaches described 
above. Two experienced operators (T.P. and T.C.) quantified uptake 
values on each of the scan pairs, on 2 occasions separated by ≥2-week 
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3  Pawade et al  18F-Fluoride PET Scan–Rescan Reproducibility in Aortic Stenosis 
Figure 1. Creation of coregistered en face short-axis positron emission tomography (PET)/computed tomography (CT) images of the 
aortic valve. First, the CT angiogram is reorientated to get into the approximate plane of the aortic valve by lining up the axial cross hair 
(purple in this example) using the images in the coronal (A) and sagittal planes (C). This creates an approximate cross-sectional image of 
the aortic valve in the axial frame (B). Scrolling down in the axial frame, the center of the crosshairs is then placed over the exact point 
at which the right coronary cusp disappears, identifying the base of that leaflet (D). Similarly, the base of the noncoronary cusp is identi-
fied, and orthogonal planes adjusted so that the purple plane goes through the base of both these 2 cusps (D). Finally, the base of the 
left coronary cusp is found by rotation of the axial crosshairs so that first the cusp comes into view. The image is then slowly rotated in 
the opposite direction until the point where the leaflet first disappears (the base) is again found (F). This produces an en face image of the 
valve aligned with the base of all 3 leaflets (G). Adjacent 3-mm slices are then created in that plane and used for subsequent assessment. 
These slices are fused with the 18F-fluoride PET images (H) and careful coregistration performed in 3 dimensions to ensure accurate 
alignment between the PET and CT images (I).
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interval to avoid recall bias. Observers were blinded to both their own 
previous measurements and those of the other operator.
Spatial Resolution
The effect of our modifications on spatial resolution and scan–rescan 
reproducibility were then assessed in comparison with the original 
approach. First, we assessed the ability of the technique to localize 
increased 18F-fluoride activity to individual valve leaflets and their 
different regions. This was done visually using a standardized method 
for windowing the fused PET/CT images that incorporated the blood-
pool activity in right atrium as the minimum. Scan–rescan and ob-
server agreements were assessed.
Statistical Analysis
Continuous variables were expressed as mean±SD, and categori-
cal variables were expressed as total and percentage. Kappa sta-
tistics (with 95% confidence intervals) were used to measure the 
intraobserver and scan–rescan agreement in presence or absence of 
18F-fluoride uptake across coronary cusps. The κ values were inter-
preted as follows: poor <0.20, fair 0.21 to 0.4, moderate 0.41 to 0.60, 
good 0.61 to 0.80, and very good >0.81.
Intraobserver, interobserver, and scan–rescan reproducibility 
of several 18F-fluoride PET uptake approaches were analyzed and 
presented using Bland–Altman analysis and percentage error.11 
Variability in the different techniques was expressed using the width 
of the 95% limits of agreement from Bland–Altman analyses. For 
the final approach, we considered the scan–rescan reproducibility to 
be good and acceptable for use in our future trial if the width of the 
95% limits of agreement were within ±0.2 for the TBRMDSmean mea-
surements. Percentage errors for the mean bias were calculated using 
twice the SD of the difference divided by the overall mean measure-
ments. The intraclass correlation coefficient was used to examine the 
reliability for both intra and interobserver variability.
Statistical analysis was performed using SAS for Windows ver-
sion 9.4. Graphs were produced using PRISM version 6.0 for Mac.
Results
Patient Characteristics
Fifteen patients (73±7 years, 67% men) had 2 scans (Table 1), 
3.9±3.3 weeks apart between November 2014 and May 2015. 
Seven patients had mild aortic stenosis, 4 had moderate and 4 
had severe aortic stenosis. In 3 participants, the between-scan 
interval exceeded 4 weeks (5 weeks, 8 weeks, and 14 weeks). 
The dose of 18F-fluoride was similar on each visit (123±8 and 
125±4 MBq; P=0·49).
Altered PET Acquisition and Image Quality
Good image quality allowing complete image analysis was 
achieved on all 15 scan pairs. The prolonged bedtimes of 30 
minutes did not result in increased patient motion during the 
18F-fluoride PET scans. The impact of each stepwise change 
in the acquisition and analysis protocol on scan–rescan repro-
ducibility is summarized in Table 2.
On visual assessment, contrast CT imaging of the valve 
provided much clearer anatomic detail of the leaflets and valve 
structure compared with noncontrast CT (Figure 2). This made 
it technically easier to get into the true plane of the valve and 
allowed more accurate regions of interest to be drawn around 
its perimeter (Figures 1 and 2). Coregistration with ECG-gated 
PET data then allowed localization of 18F-fluoride uptake to 
individual leaflets and their different regions. This was pre-
viously impossible using noncontrast CT and nongated PET. 
Most commonly increased activity was observed across all 3 
coronary cusps (n=10), it involved 2 cusps in 4 patients and 
was isolated to 1 cusp in just 1 patient. The noncoronary cusp 
was involved in all patients apart from that latter case. Activity 
was most frequently observed at the valve commissures: the 
Table 1. Patient Characteristics
 n (%) Total=15
Demographics
  Age 73.3±7.4
  Male sex 10 (67)
Vital signs
  Body mass index, kg/m2 29.7±5.6
  Pulse, beats/min 67.7±15.5
  Body surface area, m2 1.9±0.2
  Mean arterial pressure, mm Hg 100.1±9.3
  Smoker status 
   Current 1 (7)
   Never 9 (60)
   Ex 5 (33)
Symptoms
  Chest pain 4 (27)
  Breathlessness 7 (47)
  Syncope 2 (13)
Duration between scans
  Weeks 3.9±3.3
Relevant medical history
  Hypertension 11 (73)
  CABG 2 (13)
  PCI 4 (27)
  Liver disease 1 (7)
  Rheumatic fever 0 (0)
  MI 3 (20)
  Hypercholesterolemia 10 (67)
  Diabetes mellitus 4 (27)
  Renal disease 0 (0)
  TIA/CVA 2 (13)
Laboratory results
  Serum creatinine, mg/dL 70.1±11.2
Normal eGFR 14 (93)
Concomitant medications
  ACE inhibitor 6 (40)
  AIIRB 3 (20)
  β-Blocker 7 (47)
  Statin 9 (60)
ACE indicates angiotensin converting enzyme; AIIRB, angiotensin II receptor 
blocker; CABG, coronary artery bypass grafting; CVA, cerebrovascular accident; 
eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PCI, 
percutaneous coronary intervention; and TIA, transient ischemic attack.
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point where the valve cusps meet the aortic ring (n=10) and at 
the tips where the leaflets coapt during diastole (n=8; Figure 2).
When examining intraobserver reproducibility for 
detecting the presence or absence of 18F-fluoride uptake 
on individual valve leaflets, this was very good for the right 
coronary cusp (κ=1.00), good for the noncoronary cusp 
(κ=0.63), and moderate for the left (κ=0.58) coronary cusps. 
The scan–rescan agreement was good for the right coronary 
cusp (κ=0.76), good for the noncoronary cusp (κ=0.63), and 
very good for the left coronary cusp (κ=0.81) coronary cusps 
(Tables 3 and 4).
Effect of Altered Image Analysis on PET 
Reproducibility
Interobserver and intraobserver reproducibility was good 
using both the original and modified approaches as previously 
reported. Intraclass correlation coefficient values for intra- and 
interobserver reproducibility were 0.88 and 0.80, respectively 
(Table 5). However, the scan–rescan reproducibility of our orig-
inal approach produced percentage errors of ±26% and ±27% 
for the mean and maximum SUV measurements, respectively 
(Table 2). Scan–rescan reproducibility for TBR measurements 
were disappointing with percentage errors of ±63% and ±65%.
Blood-Pool Measurements
The percentage error of our original TBR values was dou-
ble that of the SUV values, suggesting a problem with our 
blood-pool measurements. Interestingly, a stepwise and non-
physiological reduction in our original brachiocephalic vein 
measurements was observed on moving cranially up the axial 
slices away from the heart and into the lung. On average, a 
20% difference in values was observed between the top and 
bottom slices, but this difference could be as high as 66%. 
By comparison, blood-pool sampling from the right atrium 
was easier to perform, allowed larger regions of interest to be 
drawn, and was consistent, demonstrating a <1% difference 
in measurements acquired on adjacent slices (Figure 3).
Sampling the blood pool in the right atrium led to a sub-
stantial improvement in the scan–rescan reproducibility of 
all our TBR measurements. Indeed, after implementing this 
approach, the reproducibility of our TBR values consistently 
outperformed those for SUV values with percentage errors 
of between ±12% and ±22% for mean and maximum val-
ues, respectively. In contrast, the approach of subtracting the 
blood-pool uptake from the tissue SUV to produce corrected 
aortic valve SUV measures did not greatly improve repro-
ducibility resulting in percentage errors of ±43% and ±39% 
for mean and maximum measurements, respectively, despite 
similar limits of agreement (Table 2).
Considerable variation was observed in 18F-fluoride 
blood-pool PET activity across our population (blood-pool 
SUV 1.10±0.35) and even between different scans on the 
same patients. This is likely related to physiological variation 
in the distribution of the tracer.
Table 2. Bland–Altman Values and Percentage Errors for Each Stepwise Change to the Image Acquisition and Analysis Technique
 
Mean Values Maximum Values
Overall 
Mean
Difference
95% Limits of 
Agreement % Error
Overall 
Mean
Difference
95% Limits of 
Agreement
% 
ErrorMean SD Mean SD
Original approach
  Whole valve, ungated PET, 
noncontrast CT
          
   Original standard uptake value 1.523  0.008 0.194 −0.373 to 0.389 26 1.955 0.094 0.263 −0.421 to 0.608 27
   Original tissue to background 
ratio (using brachiocephalic)
1.439  0.047 0.451 −0.836 to 0.930 63 1.869 0.154 0.612 −1.045 to 1.354 65
  RA blood-pool correction           
   Corrected standard uptake 
value (subtracting RA)
0.425  0.008 0.091 −0.170 to 0.186 43 0.858 0.094 0.168 −0.236 to 0.423 39
   Tissue to background ratio 
(using RA)
1.418 −0.002 0.086 −0.171 to 0.167 12 1.842 0.064 0.200 −0.328 to 0.456 22
  Most diseased segment approach           
   Standard uptake value 1.652  0.007 0.207 −0.400 to 0.413 25 2.129 0.131 0.265 −0.389 to 0.651 25
   Tissue to background ratio 
(using RA)
1.547 −0.005 0.075 −0.151 to 0.142 10 2.012 0.107 0.145 −0.177 to 0.391 14
Final approach
  RA blood pool, most diseased 
segment, gated PET, contrast CT
          
   Final standard uptake value 1.662  0.044 0.291 −0.527 to 0.615 35 2.528 0.275 0.633 −0.966 to 1.515 50
   Final tissue to background 
ratio (using RA)
1.546 −0.046 0.078 −0.199 to 0.107 10 2.385 0.111 0.439 −0.750 to 0.971 37
CT indicates computed tomography; PET, positron emission tomography; and RA, right atrium.
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MDS Approach
The MDS technique improved the technical ease of image 
analysis, removing the difficulty in deciding on the upper and 
lower limits of the valve in the z-plane. This translated into 
further improvements in scan–rescan reproducibility for mean 
TBR values with the percentage error for TBRMDSmean mea-
surements reduced to ±10%. Similarly, maximum TBR values 
were optimized on addition of the MDS approach (percentage 
error TBRMDSmax ±14%) as were the SUV measurements (per-
centage errors: SUVMDSmean ±25%; SUVMDSmax ±25%; Table 2).
Final Approach: Addition of Contrast-CT and 
ECG-Gated PET
The addition of contrast CT and ECG-gated PET data, while 
markedly improving image quality as described above, did not 
have a major effect on scan–rescan reproducibility. Reproduc-
ibility of our final approach, however, remained good with 
a percentage error of ±10% for TBRMDSmean measurements 
(Figure 4). This, combined with its ability to localize PET 
uptake to individual leaflets, made the final approach our 
preferred strategy. TBRMDSmean values using the final approach 
did not show any proportional bias with disease severity (Fig-
ure I in the Data Supplement) and were again superior to the 
equivalent SUVMDSmean values (percentage error ±35%) and to 
measurements quantifying maximum valvular 18F-fluoride 
uptake, which were less reproducible after the addition of 
gated-PET and contrast-CT (percentage errors: SUVMDSmax 
±50% and TBRMDSmax ±37%, respectively; Table 2).
Discussion
In this study, we have systematically investigated the acqui-
sition and analysis of 18F-fluoride PET imaging of the aor-
tic valve. First, we have improved the spatial localization of 
tracer uptake using ECG-gated PET data and contrast CT 
imaging, so that activity can now be localized to individual 
leaflets and regions within those leaflets. This has demon-
strated that calcification activity is most commonly observed 
at sites of maximal mechanical stress: in particular, in regions 
of leaflet coaptation and at the commissures. Second, we have 
improved the scan–rescan reproducibility by using blood-pool 
sampling of right atrium and the MDS methodology and ulti-
mately demonstrated good agreement for repeat TBRMDSmean 
measurements in the valve (percentage error ±10%). This has 
important implications for application to future clinical trials, 
indicating that 18F-fluoride might provide a useful imaging 
end point of drug efficacy.
Figure 2. Improved localization of positron emission tomography (PET) signal within the aortic valve and its leaflets. Paired nongated, 
noncontrast PET/computed tomography (CT) scans (original approach A–C and G–I) and gated, contrast-enhanced PET/CT images (final 
approach D–E and J–L). Images demonstrate the typical distribution of the tracer uptake within the valve at sites of increased mechanical 
stress, that is, at the leaflet tips (left: A–F) and at the commissures (right: G–L).
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In this study, we have modified our previous image acqui-
sition protocol to include contrast-enhanced CT imaging of the 
aortic valve, thereby providing greater definition of the indi-
vidual valve leaflets and their components. Moreover, we have 
included ECG-gated PET data to reduce the effects of cardiac 
motion and more accurately localize the pattern of activity on 
to the valve. The combined effect of these changes has been 
to improve the spatial localization of PET activity within the 
valve, which after accurate 3D coregistration, is now possible 
within specific regions of individual leaflets. This has demon-
strated that 18F-fluoride activity predominantly localizes to 
sites of increased mechanical stress within the valve, support-
ing mechanical injury as a key driver to the disease process. 
For example, 18F-fluoride activity was observed at the edges 
of the valve leaflets exactly at the sites of leaflet impact during 
valve closure. Additionally, uptake was observed at the valve 
Table 3. Scan–Rescan and Intraobserver Reproducibility for Presence or Absence of 18F-Fluoride Uptake
Subject
Right Coronary Cusp Noncoronary Cusp Left Coronary Cusp
1a 1b 2 1a 1b 2 1a 1b 2
1 + + + + + + + + −
2 + + + + + + + + +
3 + + + − + + − + −
4 + + + + + + + + +
5 + + + + + + + + +
6 + + + − − − − − −
7 + + + + + + + + +
8 − − − + + + + + +
9 + + + + + + + + +
10 + + + + + + + + +
11 − − − + + + + + +
12 + + − + + + − − −
13 + + + + + + + + +
14 + + + + + + + − +
15 + + + + + + + + +
Presence or absence of 18F-fluoride PET signal is denoted (+ and −, respectively) for each individual valve leaflet. The distribution of 18-fluoride signal on scan 1 
images (1a) were reassessed (1b) to assess intraobserver reproducibility and compared with scan 2 (2) to determine scan–rescan reproducibility. PET indicates positron 
emission tomography.
Table 4. Kappa Statistics for Interobserver and Scan–Rescan Agreement for 18F-Fluoride PET Signal Distribution
 
Scan 1 (Reading 2)
 
 
Scan 2
Absence Presence Absence Presence
Right coronary cusp
  Scan 1 
(first reading)
Absence 2 0 Scan 1 
(first reading)
Absence 2 0
Presence 0 13 Presence 1 12
  Intraobserver agreement 1.00, 95% CI (0.00–0.00 Scan/rescan agreement 0.76, 95% CI (0.32–1.00)
Noncoronary cusp
  Scan 1 
(first reading)
Absence 1 1 Scan 1 
(first reading)
Absence 1 1
Presence 0 13 Presence 0 13
  Intraobserver agreement 0.63, 95% CI (0.00–1.00) Scan/rescan agreement 0.63, 95% CI (0.00–1.00)
Left coronary cusp
  Scan 1 (first 
reading)
Absence 2 1 Scan 1 
(first reading)
Absence 3 0
Presence 1 11 Presence 1 11
  Intraobserver agreement 0.58, 95% CI (0.07–1.00) Scan/rescan agreement 0.81, 95% CI (0.47–1.00)
The numbers of presence or absence of 18F-fluoride for right coronary cusp, noncoronary cusp, and left coronary cusp are provided. κ Statistics and 95% CIs 
for intraobserver (ie, scan 1 [first reading] vs scan 1 [second reading]) and scan–rescan (ie, scan 1 [first reading] vs scan 2) agreement are also shown. CI indicates 
confidence interval; and PET, positron emission tomography.
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commissures where mechanical stress is concentrated before 
being transferred to the aortic wall.12,13 Although these find-
ings need to be confirmed in larger studies with further refine-
ment of thresholding techniques, they here provide key insight 
into the triggers to calcification activity in aortic stenosis and 
the importance of mechanical injury. Recent data have indi-
cated that the relationship between the valve calcium burden 
and hemodynamic obstruction is not perfect.14,15 The ability of 
PET to accurately localize calcification activity may be useful 
in trying to understand whether calcium formation at different 
sites of the valve has different hemodynamic impacts.
We have modified our image analysis protocol, optimiz-
ing the scan–rescan reproducibility of 18F-fluoride imaging 
in the aortic valve using several different approaches. To date, 
it has been standard practice for 18F-fluorodeoxyglucose PET 
to measure the blood-pool SUV in the brachiocephalic vein.16 
This has the benefit of avoiding contamination of myocar-
dial 18F-fluorodeoxyglucose uptake that would overestimate 
the blood-pool activity if measured in the heart. However, 
this benefit does not exist for 18F-fluoride, which has no 
background myocardial uptake. We, therefore, measured 
blood-pool activity in both the right atrium and the brachio-
cephalic vein. Measurements in the right atrium are easily 
performed on the en face (short-axis) images of the valve and 
resulted in much more consistent blood-pool measurements. 
Moreover, this approach led to a dramatic improvement in 
the scan–rescan reproducibility of our TBR measurements 
such that they then outperformed equivalent SUV measures. 
We think that sampling the blood-pool activity in the right 
atrium improved reproducibility because these measurements 
are less susceptible to the partial volume effects of adjacent 
lung tissue and because any minor inaccuracies in coreg-
istration with the PET signal will not have a great impact. 
Furthermore, it seems important to correct for variations in 
background blood-pool activity that can occur between scans 
perhaps because of minor changes in renal function, tracer 
dose, and pharmacokinetic distribution. Chen et al9 recently 
surmised that subtracting the blood pool from tissue SUV 
would improve accuracy. However, our study findings did 
not support this, and their approach produced lower TBR 
values, thereby increasing the percentage error of our repeat 
measurements.
Another major improvement in reproducibility was obtained 
using the MDS approach: measuring activity in the 2 hottest 
adjacent slices in the valve, rather than attempting to sample 
the entire valve. The major advantage of this technique is that 
it removes the considerable difficulty in deciding the limits and 
boundaries of the valve. Such uncertainty can lead to major dif-
ferences in valve measurements because uptake is much lower 
at the extremes of the valve where the volume of tissue is small 
and inclusion of extraneous tissue will dilute down mean values.
In this article, although our stepwise changes to the proto-
col generally improved the reproducibility of mean measures 
of PET uptake, the effects on maximum measures were more 
variable. This finding is somewhat at odds with experience 
in oncology where the maximum values are often preferred. 
This may reflect the use of contrast-enhanced CT (not used 
in cancer imaging), which allowed accurate and reproducible 
regions of interest to be drawn around the perimeter of the 
valve, facilitating reproducible measurement of mean PET 
uptake. In addition, it may reflect ECG gating of the PET data, 
which discards 75% of the counts, potentially having a greater 
detrimental impact on maximum values (which rely on counts 
from only a few pixels and are therefore particularly suscep-
tible to noise) than mean values. It is possible that advanced 
image analysis approaches that model and correct for cardiac 
motion without discarding any PET data will improve the 
reproducibility of TBRMDSmax measurements as has recently 
been described for coronary 18F-fluoride activity.17
This is the first study to assess scan–rescan reproducibil-
ity for 18F-fluoride uptake in the aortic valve. For a technique 
to be clinically applicable, clinicians and clinical researchers 
need the reassurance that a given methodology is robust and 
reproducible. We have demonstrated this here. However, we 
acknowledge that scan–rescan reproducibility does not nec-
essarily translate to accuracy and sensitivity. The value of 
18F-fluoride as an imaging marker of calcification activity 
will ultimately be determined by its ability to predict disease 
progression and to detect changes in calcification activity in 
response to novel therapies. These aspects are both currently 
being studied within the SALTIRE 2 clinical trial. We have 
already shown that the TBRMDSmean can predict disease progres-
sion and clinical events in patients with aortic stenosis.18 We 
can now report TBRMDSmean measurements, made using our opti-
mized image acquisition and analysis protocols, can quantify 
valvular 18F-fluoride activity with good reproducibility and a 
10% error. This translates directly into the requirement for low 
patient numbers for studies investigating the effects of interven-
tions on 18F-fluoride PET uptake (as a marker of calcification 
activity), because any true effect will not be swamped by noise 
within the measuring technique. Indeed, based on our repro-
ducibility data, we have provided estimates of the sample sizes 
required for different effect sizes (Figure 4). For example, 57 
patients would be required in each group to detect a 10% differ-
ence in mean 18F-fluoride activity based on 80% power and an 
α error probability of 0.05. However, although these estimates 
provide a framework for minimum sample sizes, they should 
be interpreted with a degree of caution, because they assume 
a perfect agreement between changes in the TBRMDSmean signal 
and underlying changes in valve calcification activity.
Limitations
We acknowledge the small sample size in this study; how-
ever, it is similar to that used in previous studies examining the 
Table 5. Intra-/Interobserver Variability of 18F-Fluoride PET 
Uptake (Expressed as a Continuous Variable)
 
Difference
95% Limits of Agreement ICCMean SD
Intraobserver* 0.053 0.124 −0.189 to 0.296 0.876
Intraobserver† 0.028 0.083 −0.134 to 0.190 0.979
Interobserver‡ −0.092 0.166 −0.418 to 0.234 0.796
ICC indicates intraclass correlation; and PET, positron emission tomography.
*Rater 1 scan 1 (first reading) vs rater 1 scan 1 (second reading).
†Rater 2 scan 1 (first reading) vs rater 2 scan 1 (second reading).
‡Rater 1 scan 1 (first reading) vs rater 2 scan 1 (first reading).
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reproducibility of vascular PET19and, in part, reflects attempts 
to minimize the radiation exposure associated with repeat 
PET/CT imaging. Moreover, although previous studies have 
indicated that 18F-fluoride uptake correlates with histologi-
cal markers of calcification activity and accurately predicts 
the progression in the CT calcium score, we currently lack 
data to show that 18F-fluoride is modifiable with drug therapy. 
Largely, this is because no drug has yet demonstrated an abil-
ity to reduce disease activity in aortic stenosis, and we lack 
reliable animal models of this condition.
In conclusion, we have optimized 18F-fluoride PET-CT 
imaging in the aortic valve. Excellent localization of the PET 
signal within the aortic valve is now possible, with uptake 
observed in regions of maximal mechanical stress. Moreover, 
quantification of valvular 18F-fluoride uptake is now possible 
with good scan–rescan reproducibility. 18F-Fluoride PET-CT 
holds major promise as a method to better understand calcifi-
cation activity in aortic stenosis and as a surrogate end point 
in clinical trials assessing the efficacy of potential therapeutic 
interventions.
Figure 3. Measuring blood-pool activity 
in the brachiocephalic vein and the right 
atrium. Regions of interest for measuring 
blood-pool activity in the brachiocephalic 
vein (top) and right atrium (bottom) are 
shown in the en face of the valve (left) and 
coronal (right) planes. Note that the right 
atrium is a much larger structure allow-
ing for larger regions of interest with less 
potential for partial volume artifact prob-
lems related to poor registration. Tukey 
plot demonstrates mean standard uptake 
values (SUV) for 5 contiguous slices from 
brachiocephalic (blue) and 2 from the right 
atrium (purple). Note the variation in bra-
chiocephalic vein measurements between 
those taken most caudally vs those taken 
most cranially.
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CLINICAL PERSPECTIVE
18F-Fluoride positron emission tomography (PET) is being increasingly used as a research tool to study calcification activity 
in the vasculature. It binds preferentially to regions of newly developing microcalcification beyond the resolution of com-
puted tomography (CT) and, in aortic stenosis, correlates closely with calcification activity on histology (alkaline phospha-
tase staining). Moreover, clinical 18F-fluoride PET-CT in aortic stenosis offers accurate prediction of disease progression 
and adverse cardiovascular events. 18F-Fluoride PET-CT, therefore, has major potential to improve our understanding of the 
role of calcification in aortic stenosis and also as a surrogate end point in studies of novel therapies for this condition. This 
article adds to current literature demonstrating that optimized 18F-fluoride PET-CT in aortic stenosis can localize calcifica-
tion activity to individual leaflets and regions of the valve associated with increased mechanical stress. Moreover, it shows 
that the scan–rescan reproducibility of aortic valve PET measurements is good, with a percentage error of ±10%. These data 
strongly support the use of 18F-fluoride PET-CT as a tool to study the mechanisms underlying aortic stenosis and also as an 
end point in novel therapies for this common condition.
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SUPPLEMENTAL MATERIAL	
Table 1.  Full list of inclusion and exclusion criteria 
 
Inclusion Criteria Age >50 years 
Peak aortic jet velocity of >2.5 m/s on Doppler echocardiography  
Grade 2-4 calcification of the aortic valve on echocardiography 
Exclusion Criteria Women of childbearing potential who have experienced menarche, are premenopausal,  
Women who have not been sterilized or who are currently pregnant. 
Women who are breastfeeding  
Renal failure (estimated glomerular filtration rate of <30 mL/min)  
Inability to undergo scanning  
Allergy or contraindication to iodinated contrast 
Inability or unwilling to give informed consent 
Likelihood of non0compliance to treatment allocation or study protocol. 
Anticipated or planned aortic valve surgery in the next 6 months,  
Life expectancy less than 2 years,  
Treatment for osteoporosis with bisphosphonates or denosumab. 
Known allergy or intolerance to alendronate or denosumab, or any of their excipients 
Abnormalities of the oesophagus or conditions, which delay oesophageal/gastric emptying. 
Inability to sit or stand for at least 30 minutes. 
Hypocalcaemia 
Regular calcium supplementation  
Dental extraction within 6 months 
Long term corticosteroid use. 
History of osteonecrosis of the jaw 
Poor dental hygiene 
Major or untreated cancers 
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Figure	1.	Linear regression analysis of scan-rescan reproducibility versus calcium burden.  The mean difference between 18F-Fluoride TBRMDSmean 
measures for the 15 scan pairs is plotted against the log-transformed Computed Tomography calcium score (log10 Agatston Units).  No proportional bias is 
observed. 
	
